Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has officially confirmed its classification status regarding large corporate entities. As of April 29, 2026, the company has reviewed its standing against established applicability criteria and determined that it does not qualify as a Large Corporate. Consequently, the organization is exempt from the specific disclosure requirements mandated for entities falling under that category.
Confirmation of Corporate Classification
In a formal communication issued on April 29, 2026, Alivus Life Sciences Limited has clarified its current status concerning large corporate categorization. The leadership team confirmed that, following a thorough internal assessment of the applicability criteria, the company does not meet the necessary benchmarks to be classified as a Large Corporate.
Impact of the Disclosure
By establishing its status as a non-Large Corporate, Alivus Life Sciences Limited is not required to submit the specific annual disclosures typically associated with that designation. This announcement provides transparency to stakeholders and ensures that the company remains compliant with its reporting obligations by clearly stating which procedural mandates are applicable to its current operations.
Source: BSE
